Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 InhibitorBusiness Wire • 09/12/23
BioInvent announces achievement of a research milestone event in its collaboration with Exelixis triggering a USD 1 million milestone paymentAccesswire • 09/07/23
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry ProspectsZacks Investment Research • 09/01/23
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine TumorsBusiness Wire • 08/24/23
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical OfficerBusiness Wire • 08/23/23
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate CancerBusiness Wire • 08/21/23
Surging Earnings Estimates Signal Upside for Exelixis (EXEL) StockZacks Investment Research • 08/11/23
Exelixis (EXEL) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/02/23
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateBusiness Wire • 08/01/23